000 04524cam a2200805Ia 4500
001 ocn795706882
003 OCoLC
005 20220711174319.0
006 m o d
007 cr cnu---unuuu
008 120618s2011 enka obf 000 0 eng d
010 _z 2012419417
040 _aN$T
_beng
_epn
_cN$T
_dE7B
_dOHS
_dYDXCP
_dOCLCQ
_dOCLCF
_dOCLCO
_dEBLCP
_dIDEBK
_dOCL
_dOCLCQ
_dOCLCO
_dOCLCQ
_dAGLDB
_dOCLCQ
_dOCLCO
_dOCLCA
_dUUM
_dVNS
_dVTS
_dSTF
_dOCLCQ
_dDKC
_dOCLCO
_dOCLCQ
_dM8D
_dOCLCO
_dOCLCQ
_dOCLCA
_dVLY
_dAJS
_dOCLCO
019 _a796384634
_a821643742
_a1053886424
_a1162207755
020 _a9780199749751
_q(electronic bk.)
020 _a0199749752
_q(electronic bk.)
020 _a1280699094
020 _a9781280699092
020 _z9780199735679
020 _z0199735670
020 _a9786613676061
020 _a6613676063
029 1 _aDEBBG
_bBV040834122
029 1 _aDEBBG
_bBV043154048
029 1 _aDEBSZ
_b424599775
029 1 _aAU@
_b000054143991
035 _a(OCoLC)795706882
_z(OCoLC)796384634
_z(OCoLC)821643742
_z(OCoLC)1053886424
_z(OCoLC)1162207755
050 4 _aRC280.B8
_bB87 2011eb
060 4 _aWP 900
072 7 _aHEA
_x039030
_2bisacsh
072 7 _aMED
_x062000
_2bisacsh
082 0 4 _a616.99449061
_222
049 _aMAIN
100 1 _aBurstein, Harold J.
_9877290
245 1 0 _aTargeted therapies in breast cancer /
_cHarold J. Burstein.
260 _aOxford ;
_aNew York :
_bOxford University Press,
_c©2011.
300 _a1 online resource (54 pages) :
_billustrations
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aOxford American pocket notes
504 _aIncludes bibliographical references.
588 0 _aPrint version record.
505 0 _aCover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References.
520 _aThe development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th.
546 _aEnglish.
590 _aeBooks on EBSCOhost
_bEBSCO eBook Subscription Academic Collection - Worldwide
650 0 _aBreast
_xCancer
_xTreatment
_vHandbooks, manuals, etc.
_9877291
650 0 _aDrug targeting
_vHandbooks, manuals, etc.
_9877292
650 2 _aDrug Delivery Systems
_9165016
650 2 _aBreast Neoplasms
_xdrug therapy
_9877293
650 6 _aSein
_xCancer
_xTraitement
_vGuides, manuels, etc.
_9877294
650 6 _aMédicaments
_xCiblage
_vGuides, manuels, etc.
_9877295
650 7 _aHEALTH & FITNESS
_xDiseases
_xCancer.
_2bisacsh
_9864670
650 7 _aMEDICAL
_xOncology.
_2bisacsh
_9864671
650 7 _aBreast
_xCancer
_xTreatment.
_2fast
_0(OCoLC)fst00838313
_95390
650 7 _aDrug targeting.
_2fast
_0(OCoLC)fst00898709
_9195392
655 0 _aElectronic books.
655 4 _aElectronic books.
655 7 _aHandbooks and manuals.
_2fast
_0(OCoLC)fst01423877
_933825
776 0 8 _iPrint version:
_aBurstein, Harold J.
_tTargeted therapies in breast cancer.
_dOxford ; New York : Oxford University Press, ©2011
_z9780199735679
_w(DLC) 2012419417
_w(OCoLC)619903409
830 0 _aOxford American pocket notes.
_9235290
856 4 0 _uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=461408
938 _aEBL - Ebook Library
_bEBLB
_nEBL943380
938 _aebrary
_bEBRY
_nebr10569217
938 _aEBSCOhost
_bEBSC
_n461408
938 _aProQuest MyiLibrary Digital eBook Collection
_bIDEB
_n367606
938 _aYBP Library Services
_bYANK
_n8578561
994 _a92
_bINOPJ
999 _c2735486
_d2735486